<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221202056689N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-25</date_registration>
      <primary_sponsor>Ghoum University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of  quince oxymel on non-alcoholic fatty liver</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the therapiotic effect of quince oxymel on treatment of non-alcoholic fatty liver disease - Randomized clinical Trial, triple Blinded, placebo controlled</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67243</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization of patients will be by block randomization method. For this purpose, the volume of each block is four people, and the number of blocks required for the study is equal to 20 four-person blocks, Blinding description: A special code will be considered for each syrup and this code will be recorded on the syrup label. Only the pharmacist consultant will know about the drug codes. Medicines will be provided to the doctor and plan administrator and the patient. The code of each syrup, specific to each patient, will be inserted in the patient's file and checklist by the administrator. At the end of the study, the information and checklist form of the patients will be provided to the statistics consultant for statistical analysis, and after the data analysis, the code of the syrups will be provided to the administrator and the statistics consultant for the final analysis. syrups in intervention and comparison groups are similar according to color, smell, shape and route of use.</study_design>
      <phase>3</phase>
      <hc_freetext>Non-alcoholic fatty liver.</hc_freetext>
      <i_freetext>Intervention 1: Intervention groupPatients with fatty liver referred to the Gastroenterology Specialist Clinic, Doctors City, Qom City are selected according to the entry criteria and randomly divided into intervention and control groups. The patients of the intervention group are treated with ten milliliters of quine oxymel syrup three times a day, half an hour before meals, for twelve weeks. Intervention 2: Control group: Patients with fatty liver referred to the gastroenterology clinic of Gastroenterology Specialist Clinic, Doctors City, Qom City are selected according to the entry criteria and randomly divided into intervention and control groups. Control group patients are treated with ten milliliters of placebo three times a day, half an hour before meals for twelve weeks. The placebo is made in the laboratory of Iranian Medicine Faculty of Qom University.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data related to the outcome of the study include the changes in the grade of fatty liver in the sonography report and the changes in liver enzymes that can be shared.

When:
The access period starts 6 months after the results are published

To whom:
Researchers of academic and scientific institutions

Conditions:
Use in the treatment of patients and use in scientific articles

Where to obtain:
Dr. Fatemeh Ali Asl, Assistant Professor, Faculty of Traditional Medicine, Qom University. . Mehrdad Ababaf Shushtri, Ph.D. Specialist Assistant, Faculty of Traditional Medicine, University of Qom.
     . mehrdadababaf@yahoo,com/.Aliasl1392@gmail.com

How to obtain:
Send a request by email and receive a response within two working weeks

Comments:
This study is the first clinical trial to investigate the effect of lemon jelly in the treatment of non-alcoholic fatty liver disease.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehrdad Ababaf Shoushtari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Panzdeh Khordad Blvd., corner of the street - Faculty of Traditional Iranian Medicine</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3714848350</zip>
        <telephone>+98 25 3776 4073</telephone>
        <email>mehrdadbabaf@yahoo.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatima Ali Asl</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Panzdeh Khordad Blvd., corner of 44 St., Faculty of Traditional Iranian Medicine</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>371484850</zip>
        <telephone>+98 25 3776 4073</telephone>
        <email>Aliasl1392@gmail.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients between the ages of 20 and 65 years
are diagnosed with grade 2 or higher fatty liver based on the ultrasound report
liver enzymes that are higher than the normal level.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having diabetes
Viral hepatitis and autoimmune hepatitis
Having metabolic diseases such as Wilson's disease and hemochromatosis
History of alcohol consumption and alcoholic beverages
Liver transplant at some point in the past
Taking any type of medicine to treat fatty liver in the past one month
The patient's unwillingness to continue the plan
Severe allergy or drug complication
Pregnancy and breastfeeding
Taking Varfarin, heparin compounds and anticoagulant drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K76.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fatty (change of) liver, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention groupPatients with fatty liver referred to the Gastroenterology Specialist Clinic, Doctors City, Qom City are selected according to the entry criteria and randomly divided into intervention and control groups. The patients of the intervention group are treated with ten milliliters of quine oxymel syrup three times a day, half an hour before meals, for twelve weeks.</i_keyword>
      <i_keyword>Control group: Patients with fatty liver referred to the gastroenterology clinic of Gastroenterology Specialist Clinic, Doctors City, Qom City are selected according to the entry criteria and randomly divided into intervention and control groups. Control group patients are treated with ten milliliters of placebo three times a day, half an hour before meals for twelve weeks. The placebo is made in the laboratory of Iranian Medicine Faculty of Qom University</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Non-alcoholic fatty liver grade. Timepoint: At the beginning of the study (before the start of the intervention) and twelve weeks after the intervention. Method of measurement: ultrasound device.</prim_outcome>
      <prim_outcome>Alanine aminotransferase enzyme. Timepoint: در ابتدای مطالعه ( قبل از شروع مداخله )  و دوازده هفته بعد از مداخله. Method of measurement: Measuring the serum level of alanine aminotransferase enzyme in peripheral blood samples.</prim_outcome>
      <prim_outcome>Aspartate aminotransferase. Timepoint: در ابتدای مطالعه ( قبل از شروع مداخله )  و دوازده هفته بعد از مداخله. Method of measurement: اندازه گیری  سطح  سرمی آنزیم آسپارتات آمینو ترانسفراز در  نمونه خون محیطی.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ghoum University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-11-21</approval_date>
        <contact_name>Ethics committee of qom University of Medical Sciences</contact_name>
        <contact_address>No. 83, 4th Alley, Jihad University Street, Safashehr Street, Qom qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
